Catalyst Wire Dossier Catalyst Wire Dossier

Genome-edited hematopoietic stem and progenitor cell therapy

· Novartis Pharmaceuticals
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Genome-edited hematopoietic stem and progenitor cell therapy, covering 2026-01-08 to 2026-01-08. Get the full timeline:

Most recent: Clinical Trial Update: Study of Safety and Efficacy of Genome-edited Hematopoietic Stem and Progenitor Cells in Sickle Cell Disease (SCD) [Phase 1]

See pricing